Related references
Note: Only part of the references are listed.Remdesivir against COVID-19 and Other Viral Diseases
Jakob J. Malin et al.
CLINICAL MICROBIOLOGY REVIEWS (2021)
Shifts in global bat diversity suggest a possible role of climate change in the emergence of SARS-CoV-1 and SARS-CoV-2
Robert M. Beyer et al.
SCIENCE OF THE TOTAL ENVIRONMENT (2021)
Mechanism of SARS-CoV-2 polymerase stalling by remdesivir
Goran Kokic et al.
NATURE COMMUNICATIONS (2021)
Medicinal chemistry strategies toward host targeting antiviral agents
Xingyue Ji et al.
MEDICINAL RESEARCH REVIEWS (2020)
Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection
Emmie de Wit et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Structural Basis for RNA Replication by the SARS-CoV-2 Polymerase
Quan Wang et al.
CELL (2020)
Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency
Calvin J. Gordon et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2020)
Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir
Wanchao Yin et al.
SCIENCE (2020)
The novel zoonotic COVID-19 pandemic: An expected global health concern
Carlo Contini et al.
JOURNAL OF INFECTION IN DEVELOPING COUNTRIES (2020)
Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study
Qingxian Cai et al.
ENGINEERING (2020)
Remdesivir for the Treatment of Covid-19-Final Report
John H. Beigel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Compassionate Use of Remdesivir for Patients with Severe Covid-19
J. Grein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Remdesivir: Review of Pharmacology, Pre-clinical Data, and Emerging Clinical Experience for COVID-19
Sarah C. J. Jorgensen et al.
PHARMACOTHERAPY (2020)
Reprogramming of the Antibacterial Drug Vancomycin Results in Potent Antiviral Agents Devoid of Antibacterial Activity
Zsolt Szucs et al.
PHARMACEUTICALS (2020)
Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis
Ashleigh Shannon et al.
NATURE COMMUNICATIONS (2020)
Compassionate use of remdesivir for treatment of severe coronavirus disease 2019 in pregnant women at a United States academic center
Jennifer A. Mccoy et al.
AMERICAN JOURNAL OF OBSTETRICS & GYNECOLOGY MFM (2020)
Use of ribavirin in viruses other than hepatitis C. A review of the evidence
German Ramirez-Olivencia et al.
ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA (2019)
The evolution of antiviral nucleoside analogues: A review for chemists and non-chemists. Part II: Complex modifications to the nucleoside scaffold
Mary K. Yates et al.
ANTIVIRAL RESEARCH (2019)
Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir
Egor P. Tchesnokov et al.
VIRUSES-BASEL (2019)
Sofosbuvir, ribavirin and pegylated interferon for a daclatasvir-resistent genotype 3 hepatitis C virus: case report and review
Marcos Mucenic et al.
REVISTA DO INSTITUTO DE MEDICINA TROPICAL DE SAO PAULO (2019)
The evolution of nucleoside analogue antivirals: A review for chemists and non-chemists. Part 1: Early structural modifications to the nucleoside scaffold
Katherine L. Seley-Radtke et al.
ANTIVIRAL RESEARCH (2018)
Favipiravir as a potential countermeasure against neglected and emerging RNA viruses
Leen Delang et al.
ANTIVIRAL RESEARCH (2018)
Sustained Virological Response in Special Populations with Chronic Hepatitis C Using Interferon-Free Treatments: A Systematic Review and Meta-analysis of Observational Cohort Studies
Vinicius Lins Ferreira et al.
CLINICAL DRUG INVESTIGATION (2018)
History, epidemiology and diagnostics of dengue in the American and Brazilian contexts: a review
Tiago Souza Salles et al.
PARASITES & VECTORS (2018)
Drug Repurposing for Viral Infectious Diseases: How Far Are We?
Beatrice Mercorelli et al.
TRENDS IN MICROBIOLOGY (2018)
Nucleobases and corresponding nucleosides display potent antiviral activities against dengue virus possibly through viral lethal mutagenesis
Li Qiu et al.
PLOS NEGLECTED TROPICAL DISEASES (2018)
Host-Directed Antivirals: A Realistic Alternative to Fight Zika Virus
Juan-Carlos Saiz et al.
VIRUSES-BASEL (2018)
Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo(2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses
Dustin Siegel et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Favipiravir pharmacokinetics in Ebola-infected patients of the JIKI trial reveals concentrations lower than targeted
Thi Huyen Tram Nguyen et al.
PLOS NEGLECTED TROPICAL DISEASES (2017)
The emergence of arthropod-borne viral diseases: A global prospective on dengue, chikungunya and zika fevers
Sandra V. Mayer et al.
ACTA TROPICA (2017)
Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys
Travis K. Warren et al.
NATURE (2016)
Zika Virus and Birth Defects - Reviewing the Evidence for Causality
Sonja A. Rasmussen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea
Daouda Sissoko et al.
PLOS MEDICINE (2016)
Dose regimen of favipiravir for Ebola virus disease
France Mentre et al.
LANCET INFECTIOUS DISEASES (2015)
Post-exposure prophylaxis against Ebola virus disease with experimental antiviral agents: a case-series of health-care workers
Michael Jacobs et al.
LANCET INFECTIOUS DISEASES (2015)
First report of autochthonous transmission of Zika virus in Brazil
Camila Zanluca et al.
MEMORIAS DO INSTITUTO OSWALDO CRUZ (2015)
MERS coronavirus: diagnostics, epidemiology and transmission
Ian M. Mackay et al.
VIROLOGY JOURNAL (2015)
Mechanism of Action of T-705 Ribosyl Triphosphate against Influenza Virus RNA Polymerase
Hidehiro Sangawa et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Favipiravir (T-705), a novel viral RNA polymerase inhibitor
Yousuke Furuta et al.
ANTIVIRAL RESEARCH (2013)
Structure-Activity Relationships and Design of Viral Mutagens and Application to Lethal Mutagenesis
Laurent F. Bonnac et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
T-705 (Favipiravir) Induces Lethal Mutagenesis in Influenza A H1N1 Viruses In Vitro
Tatiana Baranovich et al.
JOURNAL OF VIROLOGY (2013)
Risk in Vaccine Research and Development Quantified
Esther S. Pronker et al.
PLOS ONE (2013)
The Ambiguous Base-Pairing and High Substrate Efficiency of T-705 (Favipiravir) Ribofuranosyl 5′-Triphosphate towards Influenza A Virus Polymerase
Zhinan Jin et al.
PLOS ONE (2013)
Role of Human Hypoxanthine Guanine Phosphoribosyltransferase in Activation of the Antiviral Agent T-705 (Favipiravir)
Lieve Naesens et al.
MOLECULAR PHARMACOLOGY (2013)
RNA 3′-end mismatch excision by the severe acute respiratory syndrome coronavirus nonstructural protein nsp10/nsp14 exoribonuclease complex
Mickael Bouvet et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Characterizing the Epidemiology of the 2009 Influenza A/H1N1 Pandemic in Mexico
Gerardo Chowell et al.
PLOS MEDICINE (2011)
Evaluation of the role of three candidate human kinases in the conversion of the hepatitis C virus inhibitor 2′-C-methyl-cytidine to its 5′-monophosphate metabolite
Nina L. Golitsina et al.
ANTIVIRAL RESEARCH (2010)
Ribavirin Therapy Inhibits Viral Replication on Patients With Chronic Hepatitis E Virus Infection
Nassim Kamar et al.
GASTROENTEROLOGY (2010)
Discovery of a β-D-2′-Deoxy-2′-α-fluoro-2′-β-C-methyluridine Nucleotide Prodrug (PSI-7977) for the Treatment of Hepatitis C Virus
Michael J. Sofia et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
The application of phosphoramidate ProTide technology to the potent anti-HCV compound 4′-azidocytidine (R1479)
Christopher McGuigan et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2009)
The phosphoramidate ProTide approach greatly enhances the activity of β-2′-C-methylguanosine against hepatitis C virus
Christopher McGuigan et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2009)
Effect of Ribavirin on the Mutation Rate and Spectrum of Hepatitis C Virus In Vivo
Jose M. Cuevas et al.
JOURNAL OF VIROLOGY (2009)
Physicochemical properties of the nucleoside prodrug R1626 leading to high oral bioavailability
Michael Brandl et al.
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY (2008)
Inhibition of feline (FIPV) and human (SARS) coronavirus by semisynthetic derivatives of glycopeptide antibiotics
Jan Balzarini et al.
ANTIVIRAL RESEARCH (2006)
Mechanisms of action of ribavirin against distinct viruses
JD Graci et al.
REVIEWS IN MEDICAL VIROLOGY (2006)
Application of phosphoramidate pronucleotide technology to abacavir leads to a significant enhancement of antiviral potency
C McGuigan et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Mechanism of action of T-705 against influenza virus
Y Furuta et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Antivirals and antiviral strategies
E De Clercq
NATURE REVIEWS MICROBIOLOGY (2004)
Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap
A Kentsis et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
A 7-deaza-adenosine analog is a potent and selective inhibitor of hepatitis C virus replication with excellent pharmacokinetic properties
DB Olsen et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Identification of a novel coronavirus in patients with severe acute respiratory syndrome
C Drosten et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
In vitro and in vivo activities of anti-influenza virus compound T-705
Y Furuta et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin
D Maag et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
RNA virus error catastrophe: Direct molecular test by using ribavirin
S Crotty et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Phosphorylation of nucleoside analog antiretrovirals: A review for clinicians
DS Stein et al.
PHARMACOTHERAPY (2001)
The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen
S Crotty et al.
NATURE MEDICINE (2000)
Effect of antimetabolite drugs of nucleotide metabolism on the anti-human immunodeficiency virus activity of nucleoside reverse transcriptase inhibitors
J Balzarini
PHARMACOLOGY & THERAPEUTICS (2000)
The structure of inosine 5′-monophosphate dehydrogenase and the design of novel inhibitors
MD Sintchak et al.
IMMUNOPHARMACOLOGY (2000)
Share Paper
